Sartorius Stedim Biotech (SSB) acquired Cellca, a Laupheim, Germany-based company that specializes in cell line and process development.
Cellca’s major customers are biopharmaceutical companies as well as biosimilar firms that do not or only partly conduct their process development in their in-house facilities. Through this acquisition, Sartorius Stedim Biotech is further expanding its service offering for process development, according to Reinhard Vogt, a member of the SSB executive committee for marketing and sales, who added that SSB has already strengthened this segment by its two recent acquisitions of BioOutsource and TAP Biosystems.
“Together with our single-use products, media and testing services, we are creating an attractive package, above all for young biopharmaceutical companies that need robust processes for the manufacture of their biologics,” he explained
Founded in 2005, Cellca has a staff of 30 employees and generated sales revenue of approximately €6 million (about $6.65 million) in 2014.